Trial reportDiabetes care2006
The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.
Trial report in Diabetes care, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02879409 (Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population), which is not on this map. Cited by 123 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?
Who cites it
123 citing papers in PubMed, 1 synthesis or guideline pooled it, 375 citations in OpenAlex.
- HbA1C variability and the risk of renal status progression in Diabetes Mellitus: a meta-analysis.PloS one · 2014Pooled it
- Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.British journal of clinical pharmacology · 2019Trial
- Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial.Diabetes care · 2018Trial
- Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial.Diabetes care · 2017Trial
- The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study.Diabetes technology & therapeutics · 2016Trial
- Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.Journal of diabetes science and technology · 2012Trial
- A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study.Diabetes care · 2011Trial
- Trial
- Do high blood glucose peaks contribute to higher HbA1c? Results from repeated continuous glucose measurements in children.World journal of pediatrics : WJP · 2008Trial
- Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes.Diabetologia · 2007Trial
- CGM-derived average glucose is more strongly associated with microvascular complications than HbA1c in type 1 diabetes.Diabetes, obesity & metabolism · 2026Observational
- Association Between Short-Term Glycemic Variability Measured by Continuous Glucose Monitoring and Early Diabetic Kidney Disease in Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Salivary microbiota signatures of periodontitis are associated with CGM-derived short-term glycaemic control in adults with type 1 diabetes: a pilot study.Frontiers in endocrinology · 2026Article
- Comparison of continuous glucose monitoring profiles during the day and night in healthy and diabetic cats.Journal of feline medicine and surgery · 2025Article
- Hybrid closed loop and intensive insulin delivery technology: Reviewing the effect of improving 'time in range' glucose levels on diabetic retinopathy.Eye (London, England) · 2025Article
- Habit-learning and decision-making circuits are susceptible to glycemic variability in type 2 diabetes: a longitudinal study.Frontiers in neuroscience · 2025Article
- The effect of HbA1C variability on the development and progression of diabetic nephropathy.Frontiers in clinical diabetes and healthcare · 2025Article
- Short-term Glycemic Variability and Its Association With Macrovascular and Microvascular Complications in Patients With Diabetes.Journal of diabetes science and technology · 2024Review
- Glycemic profile variability as an independent predictor of diabetic retinopathy in patients with type 2 diabetes: a prospective cohort study.Frontiers in endocrinology · 2024Article
- Glycemic variability: Measurement, target, impact on complications of diabetes and does it really matter?Journal of diabetes investigation · 2024Review
63 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt is not known whether glycemic instability may confer a risk of microvascular complications that is in addition to that predicted by the mean blood glucose (MBG) value alone. This study has analyzed data from the Diabetes Control and Complications Trial (DCCT) to assess the effect of glucose variability on the risk of retinopathy and nephropathy in patients with type 1 diabetes. RESEARCH DESIGN AND
methodsPre- and postprandial seven-point glucose profiles were collected quarterly during the DCCT in 1,441 individuals. The mean area under the curve glucose and the SD of glucose variability within 24 h and between visits were compared with the risk of retinopathy and nephropathy, having adjusted for age, sex, disease duration, treatment group, prevention cohort, and phase of treatment.
resultsMultivariate Cox regression showed that within-day and between-day variability in blood glucose around a patient's mean value has no influence on the development or progression of either retinopathy (P = 0.18 and P = 0.72, respectively) or nephropathy (P = 0.32 and P = 0.57). Neither preprandial (P = 0.18) nor postprandial (P = 0.31) glucose concentrations preferentially contribute to the probability of retinopathy.
conclusionsThis study has shown that blood glucose variability does not appear to be an additional factor in the development of microvascular complications. Also, pre- and postprandial glucose values are equally predictive of the small-vessel complications of type 1 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.